Sanofi U.S. - Sanofi Diabetes LogoFor U.S. Residents Only
For U.S. Residents Only Afrezza (insulin human) Inhalation Powder
IMPORTANT SAFETY INFORMATION FOR AFREZZA®
WARNING: RISK OF ACUTE BRONCHOSPASM IN PATIENTS WITH CHRONIC LUNG DISEASE
  • Acute bronchospasm has been observed in patients with asthma and COPD using Afrezza®.
  • Afrezza® is contraindicated in patients with chronic lung disease such as asthma or COPD.
Read full Important Safety Information >>
Prescribing Information
including Boxed WARNING
Medication
Guide
Now Available

Afrezza® Inhaled Insulin

Afrezza® is a rapid acting inhaled insulin to improve blood sugar control in adult patients with diabetes. Do not use Afrezza® as a substitute for long-acting insulin; Afrezza® must be used in combination with long-acting insulin in patients with type 1 diabetes and some patients with type 2 diabetes. Do not use Afrezza® to treat diabetic ketoacidosis. Afrezza® is not recommended in patients who smoke or who have recently stopped smoking (less than 6 months). So ask your doctor if Afrezza® could be right for you.

Afrezza (insulin human) Inhalation Powder Inhaler

Sign up for Afrezza® information & updates

If you’re a person with diabetes, you can learn more about Afrezza® by signing up below.

Sanofi U.S. respects your interest in keeping your personal information private. We will not sell or rent your information to any outside mailing lists. For more information, click to view our Privacy Policy.
By clicking the Register Now button, I agree that the information provided above may be used by Sanofi U.S., its affiliates and the business service companies working with Sanofi U.S. to provide me with this additional information and to develop products and services concerning diabetes that may include market research.
Get the Afrezza Savings Card

Savings Card

Sign up and get the Afrezza® COACH support program.
Certain restrictions apply.*

Apply now
Afrezza Prescribing Information

Afrezza® Prescribing Information

Read the full Safety and
Prescribing Information.

Download PDF
Afrezza Medication Guide

Afrezza® Medication Guide

Read the Medication Guide.

Download PDF

Risk Evaluation and Mitigation Strategy (REMS)

Learn more and access Important Safety Information.

Program Details

INDICATIONS AND USAGE FOR AFREZZA®

Afrezza® is a rapid acting inhaled insulin indicated to improve glycemic control in adult patients with diabetes mellitus.

Limitations of Use:

IMPORTANT SAFETY INFORMATION FOR AFREZZA®

WARNING: RISK OF ACUTE BRONCHOSPASM IN PATIENTS WITH CHRONIC LUNG DISEASE
  • Acute bronchospasm has been observed in patients with asthma and COPD using Afrezza®.
  • Afrezza® is contraindicated in patients with chronic lung disease such as asthma or COPD.
  • Before initiating Afrezza®, perform a detailed medical history, physical examination, and spirometry (FEV1) to identify potential lung disease in all patients.

CONTRAINDICATIONS

Afrezza® is contraindicated in patients with the following:

WARNINGS AND PRECAUTIONS

Afrezza® is contraindicated in patients with chronic lung disease such as asthma or COPD. Prior to initiating therapy, patients should be evaluated with a medical history, physical examination and spirometry (FEV1) to identify potential underlying lung disease. Acute bronchospasm has been observed following Afrezza® dosing in patients with asthma and patients with COPD. The long-term safety and efficacy of Afrezza® in patients with chronic lung disease has not been established.

Monitor blood glucose in all patients treated with insulin. Modify insulin regimen and dose cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type, or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment.

Hypoglycemia is the most common adverse reaction of insulin therapy, including Afrezza®, and may be serious and life-threatening. Patients and caregivers must be educated on mitigating the risks associated with hypoglycemia.

Afrezza® has been shown to cause a decrease in lung function as measured by FEV1. In clinical trials lasting up to 2 years, Afrezza treated patients experienced a small (40 ml) but greater FEV1 decline than comparator treated patients.Therefore, pulmonary function should be assessed with spirometry at baseline, after the initial 6 months of therapy and annually thereafter even in the absence of pulmonary symptoms. More frequent lung function assessment should be considered in patients with pulmonary symptoms, e.g., wheezing, bronchospasm, breathing difficulties, or cough.

In Afrezza® clinical trials, 2 cases of lung cancer were reported in patients exposed to Afrezza® while no cases were reported for the comparators. Two additional cases of lung cancer (squamous cell) were reported in non-smokers exposed to Afrezza® reported after the trial completion. In patients with active lung cancer, a prior history of lung cancer, or in patients at risk of lung cancer, consider whether the benefits of Afrezza® outweigh the risks.

Increase the frequency of glucose monitoring and consider an alternate route of administration of insulin in patients at risk for diabetic ketoacidosis (DKA). In clinical trials enrolling subjects with type 1 diabetes, DKA was more common in subjects receiving Afrezza® (0.43%; n=13) than in subjects receiving comparators (0.14%; n=3).

As with all insulins, Afrezza® use can lead to life-threatening hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Closely monitor potassium levels in patients at risk of hypokalemia and treat if indicated.

Severe, life-threatening, generalized allergy, including anaphylaxis, can occur. Discontinue Afrezza®, monitor and treat if indicated.

Fluid retention, which may lead to or exacerbate heart failure, can occur with concomitant use of thiazolidinediones (TZDs) and insulin. These patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dose reduction or discontinuation of TZD must be considered.

DRUG INTERACTIONS

Certain drugs may affect glucose metabolism, increasing the risk of hypoglycemia or decreasing the blood glucose lowering effect of Afrezza®. Dose adjustment and increased frequency of blood glucose monitoring may be required. The signs and symptoms of hypoglycemia may be reduced when taking Afrezza® concomitantly with beta-blockers, clonidine, guanethidine, and reserpine.

ADVERSE REACTIONS

The most common adverse reactions associated with Afrezza® include hypoglycemia, cough (including productive cough), throat pain or irritation, and headache.

Click here for Full Prescribing Information for Afrezza® including Boxed WARNING.
Click here to learn more about Sanofi's commitment to fighting counterfeit drugs.

*Offer is not valid for patients if their prescriptions are paid in part or in full by any state or federally funded programs, including, but not limited to, Medicare or Medicaid, Medigap, VA, DOD or TriCare. Offer is not valid where prohibited by law. Sanofi US reserves the right to rescind, revoke, or amend this offer without notice. Maximum benefit is $150 per prescription depending on your out-of-pocket costs for the duration of the program. Eligibility criteria: Only patients who reside in the United States, Puerto Rico, Guam or the U.S. Virgin Islands can participate in this program. If you have any questions about this program, please call 866-991-2840, or if you have questions about Afrezza®, talk to your healthcare professional.